Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 73 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Importance Increasing evidence suggests that sleep-disordered breathing (SDB) increases the risk of developing Alzheimer clinical syndrome. Objective To determine which brain changes are associated with the presence of SDB in older individuals who are cognitively unimpaired, including changes in amyloid deposition, gray matter volume, perfusion, and glucose metabolism. Voxelwise between-group comparisons were performed for each neuroimaging modality, and secondary analyses aimed at identifying which SDB parameter (sleep fragmentation, hypoxia severity, or frequency of respiratory disturbances) best explained the observed brain changes and assessing whether SDB severity and/or SDB-associated brain changes are associated with cognitive and behavioral changes. Results Of 157 participants initially assessed, 137 were enrolled in the Age-Well clinical trial, and 127 were analyzed in this study. These results support the need to screen and treat for SDB, especially in asymptomatic older populations, to reduce Alzheimer disease risk.

What this study adds

Evidence grade: High

This is a cross-sectional study of 157 participants. This secondary analysis of a randomized clinical trial examined which brain changes, including amyloid deposition, gray matter volume, perfusion, and glucose metabolism, are associated with sleep-disordered breathing in cognitively unimpaired older adults. Reported effect size: 63.0%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

André, C., Rehel, S., Kuhn, E., Landeau, B., Moulinet, I., Touron, E., et al. (2020). Association of Sleep-Disordered Breathing With Alzheimer Disease Biomarkers in Community-Dwelling Older Adults: A Secondary Analysis of a Randomized Clinical Trial. JAMA neurology. https://doi.org/10.1001/jamaneurol.2020.0311

Vancouver

André C, Rehel S, Kuhn E, Landeau B, Moulinet I, Touron E, et al. Association of Sleep-Disordered Breathing With Alzheimer Disease Biomarkers in Community-Dwelling Older Adults: A Secondary Analysis of a Randomized Clinical Trial. JAMA neurology. 2020. doi:10.1001/jamaneurol.2020.0311. PMID: 32202593.

BibTeX

@article{andre2020-32202593,
  author  = {André, C. and Rehel, S. and Kuhn, E. and Landeau, B. and Moulinet, I. and Touron, E. and Ourry, V. and Le Du, G. and others},
  title   = {{Association of Sleep-Disordered Breathing With Alzheimer Disease Biomarkers in Community-Dwelling Older Adults: A Secondary Analysis of a Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2020},
  doi     = {10.1001/jamaneurol.2020.0311},
  pmid    = {32202593},
  url     = {https://doi.org/10.1001/jamaneurol.2020.0311}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This secondary analysis of a randomized clinical trial examined which brain changes, including amyloid deposition, gray matter volume, perfusion, and glucose metabolism, are associated with sleep-disordered breathing in cognitively unimpaired older adults. The authors say the results support screening and treating sleep-disordered breathing to reduce Alzheimer disease risk, but this cross-sectional analysis cannot show that treatment prevents the disease.

Study details

How this study scored 73/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 73 of 100.73 of 100 points earned27 not earned

Published in a leading specialty journal, and it is a randomized controlled trial.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record 2 / 4 JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 2 / 4 157 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 5 / 7 Cited 118 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 14.8 citations a year over 8 year(s) since 2020
Impact for its field and year 4 / 6 Cited 8.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 6 other studies in this library
Still being cited 2 / 4 Cited 47 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Géraldine Rauchs: h-index 37 (OpenAlex, whole career)
Institution's track record 3 / 3 Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 13 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 32202593)
Free to read 0 / 2 Behind a paywall — scores zero
Total 73 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Treatments from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →